Feb 27, 2014 by Seth Robey3 Things to Watch When Isis Pharmaceuticals Reports 2013 EarningsThis RNA therapeutics powerhouse should provide some insightful updates as it enters a critical point in its growth.
Feb 18, 2014 by Seth RobeyThe Amazon.com and Facebook of Health CareAn investment in athenahealth is an investment in CEO Jonathan Bush's vision for an interconnected health care internet.
Feb 12, 2014 by Seth Robey3 Trends That Could Define Drug Discovery in 2014These clear trends could help investors identify winning companies in 2014 and beyond.
Feb 3, 2014 by Seth RobeyTiming is Everything for this Health Care IT ProviderVeeva Systems has an innovative platform to meet the growing demand for cost-cutting in the health care sector.
Feb 3, 2014 by Seth RobeyTime for a Turnaround at Teva Pharmaceuticals Industries Ltd?Are Teva's management and patent woes finally a thing of the past?
Jan 22, 2014 by Seth Robey2014: The Year of Personalized MedicineAfter a 2013 of massive improvements to cancer therapy, will 2014 be the year doctors can quickly determine which patients will benefit from which therapies?
Jan 22, 2014 by Seth RobeyWhat to Watch When Bristol-Myers Squibb Reports End of Year EarningsCan Bristol-Myers put its capital to good use and push its hepatitis and oncology segments to success?
Jan 6, 2014 by Seth RobeyA Busy Week for Cardiac Health at the FDAChelsea, Merck, and Johnson & Johnson state their cases for approval in front of an FDA panel. Here's everything you need to know to stay ahead of the game.
Jan 3, 2014 by Seth RobeyCancer Immunotherapy: The Breakthrough of 2013With Roche, Merck, and Bristol-Myers Squibb posting impressive clinical trial results, immunotherapy represents a major breakthrough in treating cancer.
Dec 31, 2013 by Seth Robey3 Health Care Investments Immune From FDA ScrutinyVeeva Systems, Express Scripts, and Repligen operate in the health care space but don't rely on the good graces of FDA regulators.
Dec 10, 2013 by Seth RobeyNovartis and Merck Could Boost One Another to New HeightsAfter rumors abound that Novartis will shop its animal health unit, is an asset swap better than a sale?
Dec 5, 2013 by Seth Robey3 Biotech Flops of 20132013 was a great year for the biotech industry as a whole, but Achillion, Prosensa, and Amarin didn't share the joy.
Dec 4, 2013 by Seth RobeyCan Heart Drugs Disrupt an Emerging Breast Cancer Market?A surprising finding published last week could open a door for statins to prevent breast cancer.
Dec 2, 2013 by Seth RobeyA Health Care Portolio for the Ages: CheckupGilead, Celgene, and Johnson & Johnson have all seen catalysts investors should know about.
Nov 22, 2013 by Seth RobeyClarifying Breakthrough Designation at the FDAThe new designation will help drugs get to patients with serious diseases much more quickly, and it can spur excitement surrounding a company's stock.
Nov 17, 2013 by Seth RobeyA Shifting Paradigm in Heart Disease Could Affect These DrugmakersAmgen, Regeneron, and Sanofi are among the companies impacted by a change to the cardiologist's mindset.
Nov 8, 2013 by Seth RobeyA Busy Day of Layoffs in PharmaThe big pharma cost cutting continues as Novartis, Bristol-Myers Squibb, and Ariad Pharmaceuticals announce staff cuts.
Nov 5, 2013 by Seth Robey3 Things Investors Should Know From Isis' Earnings ReportIsis Pharmaceuticals has had an eventful year, and this quarter was no different.
Nov 5, 2013 by Seth RobeyA Health Care Portfolio for the Ages: The Platform PlayThis week we'll add a high growth prospect to our market-beating health care virtual portfolio.
Oct 25, 2013 by Seth RobeyA Health Care Portfolio for the Ages: The StalwartsIn this week's edition, we'll add two dividend-paying stalwarts, Johnson & Johnson and Abbott Labs, to our HealthyMoney CAPS virtual portfolio.
